NEW YORK (GenomeWeb) – Singulex has shipped its first Singulex Clarity system — an immunodiagnostics platform based on single-molecule counting technology — to a laboratory in Barcelona, which will validate the instrument for use as a CE-marked in vitro diagnostic system in Europe.

In addition, Singulex is planning to begin clinical studies in the US this July designed to bring the Clarity system through US Food and Drug Administration 510(k) clearance, Singulex CEO Guido Baechler recently told GenomeWeb.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.